MCID: LSH001
MIFTS: 71

Leishmaniasis

Categories: Rare diseases, Infectious diseases, Skin diseases

Aliases & Classifications for Leishmaniasis

MalaCards integrated aliases for Leishmaniasis:

Name: Leishmaniasis 12 72 49 51 40 3 41 14 69
Post-Kala-Azar Dermal Leishmaniasis 12 69
Post-Kala-Azar Dermal Infectious Disease by Leishmaniasis 12
Post Kala-Azar Dermal Leishmaniasis 12
Leishmaniasis, Cutaneous 69
Cutaneous Leishmaniasis 49
Leishmaniasis, Visceral 69
Visceral Leishmaniasis 49
Kala-Azar 49

Classifications:



Summaries for Leishmaniasis

MedlinePlus : 40 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver, and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Leishmaniasis is found in parts of about 88 countries. Most of these countries are in the tropics and subtropics. It is possible but very unlikely that you would get this disease in the United States. But you should be aware of it if you are traveling to the Middle East or parts of Central America, South America, Asia, Africa or southern Europe. Treatment is with medicines that contain antimony, a type of metal, or with strong antibiotics. The best way to prevent the disease is to protect yourself from sand fly bites: Stay indoors from dusk to dawn, when sand flies are the most active Wear long pants and long-sleeved shirts when outside Use insect repellent and bed nets as needed Centers for Disease Control and Prevention

MalaCards based summary : Leishmaniasis, also known as post-kala-azar dermal leishmaniasis, is related to cutaneous leishmaniasis and visceral leishmaniasis, and has symptoms including abnormality of the nose, pallor and splenomegaly. An important gene associated with Leishmaniasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs chloroquine and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and spleen, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae).

NIH Rare Diseases : 49 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Visceral disease can be deadly without proper treatment. Leishmaniasis is found in parts of the Middle East, Central America, South American, Asia, Africa, and southern Europe. Most of these countries are in the tropics and subtropics. It is possible but very unlikely to get this disease in the United States. Last updated: 7/6/2011

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a Neglected Tropical Disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

Wikipedia : 72 Leishmaniasis is a disease caused by parasites of the Leishmania type. It is spread by the bite of... more...

Related Diseases for Leishmaniasis

Diseases related to Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 405)
# Related Disease Score Top Affiliating Genes
1 cutaneous leishmaniasis 31.9 IFNG IL10 IL4 IL5 LMLN MPI
2 visceral leishmaniasis 31.2 HSPA4 IFNG IFNGR1 IL10 IL1B IL4
3 sleeping sickness 30.5 IL10 NOS2 SRM
4 acquired immunodeficiency syndrome 30.5 IFNG IL10 IL1B TNF
5 leprosy 3 30.3 IFNG IL10 IL4 SLC11A1 TLR2 TNF
6 chagas disease 30.2 IFNG IL10 IL1B NOS2 TLR2 TLR4
7 hematopoietic stem cell transplantation 30.1 IFNG IL10 TNF
8 lepromatous leprosy 30.0 IFNG IFNGR1 IL10 TLR2 TNF
9 panuveitis 30.0 HLA-DRB1 IL10 TNF
10 orofacial granulomatosis 30.0 IFNG IL10 IL4 TNF
11 fascioliasis 30.0 IFNG IL10 IL1B
12 hemorrhagic fever 29.9 HLA-DRB1 IFNG IL10 TNF
13 mixed connective tissue disease 29.9 HLA-DRB1 IFNG IL10 TNF
14 prostatitis 29.9 IL10 IL1B TNF
15 arthritis 29.9 HLA-DRB1 IFNG IL10 IL1A IL1B TNF
16 trypanosomiasis 29.8 IFNG IL10 IL1B IL4 TLR2 TLR9
17 melioidosis 29.7 IFNG IL10 TLR2 TLR4 TNF
18 folliculitis 29.7 IFNG IL4 IL5
19 wegener granulomatosis 29.7 IFNG IL10 ITGAM TNF
20 psoriatic arthritis 29.7 HLA-DRB1 IL1A IL1B TNF
21 cryptococcosis 29.6 IFNG IL4 TLR9
22 rheumatic disease 29.6 HLA-DRB1 IFNG IL10 IL1B TNF
23 chronic granulomatous disease 29.5 IFNG IL1B TLR9 TNF
24 schistosomiasis 29.4 IFNG IFNGR1 IL10 IL4 IL5 TNF
25 onchocerciasis 29.4 IL4 IL5 MPI
26 coccidiosis 29.3 IFNG IL10 IL4 TLR9 TNF
27 common variable immunodeficiency 29.3 IFNG IL10 IL4 TLR9 TNF
28 keratitis, hereditary 29.2 IL1B TLR2 TLR4 TLR9
29 mycobacterium tuberculosis 1 28.9 IFNG IFNGR1 IL10 IL4 SLC11A1 TLR2
30 meningitis 28.9 IFNG IL10 IL1B TLR2 TLR9 TNF
31 tonsillitis 28.7 IFNG IL1A IL1B IL4 TLR9 TNF
32 connective tissue disease 28.7 HLA-DQA1 HLA-DRB1 IFNG IL10 IL1A TLR9
33 psoriasis 28.5 IFNG IL10 IL1A IL1B IL4 TLR9
34 rheumatoid arthritis 28.5 HLA-DQA1 HLA-DRB1 IFNG IL10 IL1A IL1B
35 pulmonary tuberculosis 28.5 HLA-DRB1 IFNG IFNGR1 IL10 IL4 SLC11A1
36 aspergillosis 28.5 IFNG IL10 IL4 IL5 TLR2 TLR4
37 filariasis 28.5 IFNG IL10 IL5 TLR2 TLR4 TLR9
38 toxoplasmosis 28.4 HLA-DQA1 IFNG IL10 IL1B IL4 TLR4
39 periodontitis 28.1 IFNG IL10 IL1A IL1B IL4 TLR2
40 systemic lupus erythematosus 27.7 HLA-DQA1 HLA-DRB1 IFNG IL10 IL1B IL4
41 malaria 26.2 HLA-DRB1 HSPA4 IFNG IFNGR1 IL10 IL1A
42 mucocutaneous leishmaniasis 12.5
43 leishmaniasis, tegumentary 12.1
44 kala-azar 1 12.0
45 kala-azar 2 11.0
46 kala-azar 3 11.0
47 chronic rhinitis 10.9
48 mycoplasmal pneumonia 10.7 IFNG IL4
49 punctate inner choroidopathy 10.6 IL10 TNF
50 hyperlucent lung 10.6 IFNG IL10 IL4

Graphical network of the top 20 diseases related to Leishmaniasis:



Diseases related to Leishmaniasis

Symptoms & Phenotypes for Leishmaniasis

Human phenotypes related to Leishmaniasis:

31 (show all 24)
# Description HPO Frequency HPO Source Accession
1 abnormality of the nose 31 hallmark (90%) HP:0000366
2 pallor 31 frequent (33%) HP:0000980
3 splenomegaly 31 hallmark (90%) HP:0001744
4 weight loss 31 frequent (33%) HP:0001824
5 thrombocytopenia 31 occasional (7.5%) HP:0001873
6 pancytopenia 31 hallmark (90%) HP:0001876
7 leukopenia 31 occasional (7.5%) HP:0001882
8 abnormal bleeding 31 hallmark (90%) HP:0001892
9 anemia 31 frequent (33%) HP:0001903
10 episodic fever 31 hallmark (90%) HP:0001954
11 anorexia 31 occasional (7.5%) HP:0002039
12 hepatomegaly 31 hallmark (90%) HP:0002240
13 lymphadenopathy 31 hallmark (90%) HP:0002716
14 arthralgia 31 frequent (33%) HP:0002829
15 elevated hepatic transaminases 31 frequent (33%) HP:0002910
16 hypoalbuminemia 31 frequent (33%) HP:0003073
17 abnormal macrophage morphology 31 hallmark (90%) HP:0004311
18 increased antibody level in blood 31 frequent (33%) HP:0010702
19 abnormality of oral mucosa 31 hallmark (90%) HP:0011830
20 fatigue 31 occasional (7.5%) HP:0012378
21 night sweats 31 hallmark (90%) HP:0030166
22 papule 31 hallmark (90%) HP:0200034
23 skin plaque 31 hallmark (90%) HP:0200035
24 skin ulcer 31 hallmark (90%) HP:0200042

UMLS symptoms related to Leishmaniasis:


pruritus, fever, exanthema

GenomeRNAi Phenotypes related to Leishmaniasis according to GeneCards Suite gene sharing:

25 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.88 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.88 HSPA4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.88 HSPA4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.88 HSPA4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.88 IL10 TLR4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.88 TLR4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.88 HLA-DRB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.88 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.88 IL10 TLR4 HLA-DRB1 HSPA4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.88 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.88 HLA-DRB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.88 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.88 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.88 TLR4 HLA-DRB1 HSPA4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.88 HSPA4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.88 HLA-DRB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.88 HLA-DRB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.88 HLA-DRB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.88 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.88 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.88 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.88 TLR4
23 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.88 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.88 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.88 HSPA4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.88 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.88 IL10 HLA-DRB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.88 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.88 IL10

MGI Mouse Phenotypes related to Leishmaniasis:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 TNF HLA-DQA1 IFNG IFNGR1 IL10 IL1A
2 immune system MP:0005387 10.35 HLA-DQA1 IFNG IFNGR1 IL10 IL1A IL1B
3 cellular MP:0005384 10.33 MPI NOS2 TLR2 TLR4 TLR9 TNF
4 homeostasis/metabolism MP:0005376 10.31 IFNG IFNGR1 IL10 IL1A IL1B IL4
5 digestive/alimentary MP:0005381 10.28 IFNG IFNGR1 IL10 IL4 IL5 NOS2
6 cardiovascular system MP:0005385 10.26 IFNG IFNGR1 IL10 IL1A IL1B MPI
7 mortality/aging MP:0010768 10.22 IFNG IFNGR1 IL10 IL1B IL4 MPI
8 endocrine/exocrine gland MP:0005379 10.18 TNF HLA-DQA1 HSPA4 IFNG IFNGR1 IL10
9 integument MP:0010771 10.16 IFNG IFNGR1 IL10 IL1A IL1B IL4
10 neoplasm MP:0002006 10.11 IFNG IFNGR1 IL10 IL1A IL1B IL5
11 nervous system MP:0003631 10.1 HSPA4 IFNG IFNGR1 IL10 IL1B IL4
12 liver/biliary system MP:0005370 10.09 IFNGR1 IL10 IL4 IFNG IL5 NOS2
13 reproductive system MP:0005389 9.81 HSPA4 IFNG IFNGR1 IL10 IL4 IL5
14 renal/urinary system MP:0005367 9.8 IFNG IFNGR1 IL4 NOS2 TLR2 TLR4
15 respiratory system MP:0005388 9.56 TNF IFNG IL10 IL4 IL5 NOS2
16 skeleton MP:0005390 9.32 IFNG IFNGR1 IL10 IL1B IL4 MPI

Drugs & Therapeutics for Leishmaniasis

Drugs for Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
2
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1397-89-3 5280965 14956
3
Primaquine Approved Phase 4 90-34-6 4908
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
6
deoxycholic acid Approved Phase 4,Phase 3 83-44-3 222528
7
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
8
Paromomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 7542-37-2, 1263-89-4 165580
9 meglumine antimoniate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Chloroquine diphosphate Phase 4 50-63-5
11 Analgesics Phase 4,Phase 2,Phase 3
12 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
13 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antimalarials Phase 4
19 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
20 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
21 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1
22 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1
23 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Antirheumatic Agents Phase 4,Phase 2,Phase 3
26 Cholagogues and Choleretics Phase 4,Phase 3
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
28 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3
29 Anesthetics Phase 4
30
Ethanol Approved Phase 2, Phase 3 64-17-5 702
31
Salicylic acid Approved, Investigational, Vet_approved Phase 2, Phase 3 69-72-7 338
32
Pentamidine Approved, Investigational Phase 3,Phase 2 100-33-4 4735
33
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
34
Nitric Oxide Approved Phase 3 10102-43-9 145068
35
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
36
Imiquimod Approved, Investigational Phase 3,Phase 2 99011-02-6 57469
37
Aluminum sulfate Approved Phase 2, Phase 3, Phase 1 10043-01-3
38
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
39
Azithromycin Approved Phase 2, Phase 3 83905-01-5 53477736 447043 55185
40
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
41
Calcitriol Approved, Nutraceutical Phase 2, Phase 3 32222-06-3 5280453 134070
42
Nicotinamide Approved, Investigational, Nutraceutical Phase 2, Phase 3 98-92-0 936
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
44 Tocopherol Approved, Investigational, Nutraceutical Phase 3
45
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
46 Respiratory System Agents Phase 3
47 Salicylates Phase 2, Phase 3
48 Cyclooxygenase Inhibitors Phase 2, Phase 3
49 Dermatologic Agents Phase 2, Phase 3
50 Pharmaceutical Solutions Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 147)

# Name Status NCT ID Phase Drugs
1 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Unknown status NCT01566552 Phase 4 AMBISOME
2 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Unknown status NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
3 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
4 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
5 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
6 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4 Meglumine antimoniate
7 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
8 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
9 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4 Miltefosine
10 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh Completed NCT03311607 Phase 4 AmBisome
11 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
12 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
13 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Unknown status NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
14 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3 Pyruvic acid;Salicylic Acid
15 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
16 Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
17 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
18 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
19 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
20 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
21 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
22 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3 Pentamidine
23 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
24 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
25 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
26 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
27 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3 Imiquimod
28 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
29 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
30 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
31 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
32 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
33 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
34 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
35 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
36 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
37 Nicotinamide in the Treatment of Psoriasis Completed NCT01763424 Phase 2, Phase 3 Calcipotriol plus Nicotinamide;Calcipotriol
38 Low Antimonial Dosage in American Mucosal Leishmaniasis Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
39 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
40 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Recruiting NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
41 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Active, not recruiting NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
42 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
43 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Not yet recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
44 Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan Not yet recruiting NCT03208543 Phase 3
45 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
46 Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
47 Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
48 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
49 Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
50 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)

Search NIH Clinical Center for Leishmaniasis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: leishmaniasis

Genetic Tests for Leishmaniasis

Anatomical Context for Leishmaniasis

MalaCards organs/tissues related to Leishmaniasis:

38
Skin, Liver, Spleen, Bone, Bone Marrow, Testes, T Cells

Publications for Leishmaniasis

Articles related to Leishmaniasis:

(show top 50) (show all 2065)
# Title Authors Year
1
Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran. ( 29415078 )
2018
2
Serological diagnosis and prognostic of tegumentary and visceral leishmaniasis using a conserved Leishmania hypothetical protein. ( 29408435 )
2018
3
Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl. ( 29424815 )
2018
4
Climate and environmental factors affecting the incidence of cutaneous leishmaniasis in Isfahan, Iran. ( 29427273 )
2018
5
First case report of atypical disseminated cutaneous leishmaniasis in an opium abuser in Iran. ( 29451599 )
2018
6
Molecular detection of Leishmania (Leishmania) infantum in phlebotomine sandflies from a visceral leishmaniasis endemic area in northwestern of SALo Paulo State, Brazil. ( 29373820 )
2018
7
Health economic evaluation of moist wound care in chronic cutaneous leishmaniasis ulcers in Afghanistan. ( 29444705 )
2018
8
First detection of Leishmania DNA in Psammomys obesus and Psammomys vexillaris: Their potential involvement in the epidemiology of leishmaniasis in Tunisia. ( 29413886 )
2018
9
Exploring sand fly salivary proteins to design multi-epitope subunit vaccine to fight against visceral leishmaniasis. ( 29377223 )
2018
10
Parasitic load and histological aspects in different regions of the spleen of dogs with visceral leishmaniasis. ( 29406277 )
2018
11
Extensive Post-Kala-Azar Dermal Leishmaniasis. ( 29441312 )
2018
12
Dermoscopy of Post Kala-Azar Dermal Leishmaniasis. ( 29441313 )
2018
13
Recent progress in drug targets and inhibitors towards combating leishmaniasis. ( 29452111 )
2018
14
Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia. ( 29378537 )
2018
15
Regulatory T-Cell Dynamics in Cutaneous and Mucocutaneous Leishmaniasis due to<i>Leishmania braziliensis</i>. ( 29405108 )
2018
16
Risk profile for Leishmania infection in dogs coming from an area of visceral leishmaniasis reemergence. ( 29406075 )
2018
17
Tissue Impression Smears as a Supplementary Diagnostic Method for Histopathology in Cutaneous Leishmaniasis in Sri Lanka. ( 29345220 )
2018
18
American tegumentary leishmaniasis: diagnostic and treatment challenges in a clinical case. ( 29451600 )
2018
19
Leishmania (Viannia) braziliensis isolated from the saliva of patients in a cutaneous leishmaniasis-endemic area of northeastern Brazil. ( 29412341 )
2018
20
Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). ( 29444079 )
2018
21
Fulminant presentation of oral mucosal leishmaniasis as severe stomatitis and periodontitis. ( 29380732 )
2018
22
Epidemiological aspects of human and canine visceral leishmaniasis in State of Alagoas, Northeast, Brazil. ( 29412243 )
2018
23
Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation. ( 29329311 )
2018
24
Positive Influence of Behavior Change Communication on Knowledge, Attitudes, and Practices for Visceral Leishmaniasis/Kala-azar in India. ( 29386327 )
2018
25
Leishmania major cutaneous leishmaniasis outbreak in the Jordanian side of the Northern Jordan Valley. ( 29392995 )
2018
26
Visceral leishmaniasis in a patient with diabetes mellitus type 2 and discrete bicytopenia. ( 29375842 )
2018
27
Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis. ( 29385910 )
2018
28
Environmental factors associated with canine visceral leishmaniasis in an area with recent introduction of the disease in the State of Rio de Janeiro, Brazil. ( 29412315 )
2018
29
Cutaneous Leishmaniasis in the Metropolitan City of Multan, Pakistan, a Neglected Tropical Disease. ( 29415246 )
2018
30
Andrographolide engineered gold nanoparticle to overcome drug resistant visceral leishmaniasis. ( 29421940 )
2018
31
Some aspects of entomological determinants of Phlebotomus orientalis in highland and lowland visceral leishmaniasis foci in northwestern Ethiopia. ( 29438419 )
2018
32
Arnica Tincture Cures Cutaneous Leishmaniasis in Golden Hamsters. ( 29329207 )
2018
33
Visceral and Cutaneous Leishmaniasis Recommendations for Solid Organ Transplant Recipients and Donors. ( 29381573 )
2018
34
Leishmaniasis treatment: update of possibilities for drug repurposing. ( 28930585 )
2018
35
Isolation of Crithidia spp. from lesions of immunocompetent patients with suspected cutaneous leishmaniasis in Iran. ( 29446852 )
2018
36
Hemophagocytic Lymphohistiocytosis: A Confusing Problem of the Diagnosis of Visceral Leishmaniasis. ( 29398821 )
2018
37
Mediastinal cystic mass as atypical location of visceral leishmaniasis. ( 29398008 )
2018
38
Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. ( 29448040 )
2018
39
Unbalanced inflammatory reaction could increase tissue destruction and worsen skin infectious diseases - a comparative study of leishmaniasis and sporotrichosis. ( 29440688 )
2018
40
Cutaneous Cryptococcosis Mimicking Leishmaniasis. ( 29342402 )
2018
41
Sensitivity and specificity of an in-clinic point-of-care PCR test for the diagnosis of canine leishmaniasis. ( 29428091 )
2018
42
Liposomal Elongation Factor-1I+ Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis. ( 29441060 )
2018
43
Potential application of rLc36 protein for diagnosis of canine visceral leishmaniasis. ( 29412359 )
2018
44
Leishmanicidal and Trypanocidal Activity of Metal Complexes with 1,2,4-Triazolo[1,5-a]pyrimidines: Insights on their Therapeutic Potential against Leishmaniasis and Chagas Disease. ( 28521698 )
2017
45
The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. ( 28043177 )
2017
46
Analysis of expression of FLI1 and MMP1 in American cutaneous leishmaniasis caused by Leishmania braziliensis infection. ( 28119029 )
2017
47
Leishmania tropica: Combined debulking and imiquimod for the treatment of nonresponsive cutaneous leishmaniasis. ( 27986151 )
2017
48
Phlebotomines in an area endemic for American cutaneous leishmaniasis in northeastern coast of Brazil. ( 28902258 )
2017
49
Effect of secondary infection on epithelialisation and total healing of cutaneous leishmaniasis lesions. ( 28902290 )
2017
50
Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice. ( 28064069 )
2017

Variations for Leishmaniasis

Expression for Leishmaniasis

Search GEO for disease gene expression data for Leishmaniasis.

Pathways for Leishmaniasis

Pathways related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
2
Show member pathways
13.77 IFNG IFNGR1 IL10 IL1A IL1B IL4
3
Show member pathways
13.63 IFNG IFNGR1 IL10 IL1A IL1B IL4
4
Show member pathways
13.54 IL10 IL1A IL1B IL4 IL5 ITGAM
5
Show member pathways
13.49 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
6
Show member pathways
13.38 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL1A IL1B
7
Show member pathways
13.1 IL1A IL1B NOS2 TLR2 TLR4 TLR9
8
Show member pathways
13.01 HLA-DQA1 HLA-DRB1 HSPA4 IFNG IL10 IL1A
9
Show member pathways
12.96 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL1A IL1B
10
Show member pathways
12.82 IL1A IL1B TLR2 TLR4 TLR9 TNF
11
Show member pathways
12.79 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL4
12
Show member pathways
12.75 IFNG IFNGR1 IL1A IL1B TNF
13
Show member pathways
12.74 IL1A IL1B TLR2 TLR4 TLR9 TNF
14 12.74 IFNG IL10 IL1B IL4 TLR2 TLR9
15
Show member pathways
12.7 IFNG IFNGR1 IL10 IL1B NOS2 TLR2
16
Show member pathways
12.68 IFNG IL10 IL1B NOS2 TNF
17
Show member pathways
12.62 IFNG IL10 IL1A IL1B IL4 IL5
18
Show member pathways
12.5 IFNG IFNGR1 IL10 IL4 IL5
19
Show member pathways
12.5 IFNG IL1B IL4 IL5 TLR2 TNF
20
Show member pathways
12.46 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
21
Show member pathways
12.4 IL1A TLR2 TLR4 TLR9 TNF
22
Show member pathways
12.4 IFNG IFNGR1 IL1A IL1B TLR4 TNF
23
Show member pathways
12.39 IFNG IL1B IL4 TNF
24 12.37 IFNG IFNGR1 NOS2 TLR2 TLR4 TLR9
25 12.36 HLA-DQA1 HLA-DRB1 IFNG IL10
26
Show member pathways
12.34 IFNG IL10 IL1A IL1B IL4 IL5
27
Show member pathways
12.34 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
28 12.29 HLA-DQA1 HLA-DRB1 ITGAM TLR2 TLR4
29
Show member pathways
12.27 IFNG IFNGR1 IL1B IL4 NOS2 TLR2
30
Show member pathways
12.27 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
31 12.26 IL10 IL1A IL1B TNF
32
Show member pathways
12.23 IL1A IL1B IL5 TLR2 TLR4 TLR9
33 12.22 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
34 12.21 IFNG IFNGR1 IL1A IL1B TNF
35 12.21 IFNG IL1A IL1B IL4 NOS2 TLR4
36 12.19 IFNG IL10 IL4 IL5 ITGAM TNF
37 12.18 IFNG IL1A IL1B TNF
38 12.18 IL10 IL1A IL1B IL4 ITGAM NOS2
39
Show member pathways
12.15 HLA-DRB1 IFNG IL1B IL4 NOS2
40
Show member pathways
12.13 IFNG IFNGR1 IL10 IL1B TLR2 TLR4
41
Show member pathways
12.08 IFNG IL1B IL4 TLR2 TLR4 TLR9
42 12.05 HLA-DQA1 HLA-DRB1 IL1A IL1B IL4 IL5
43 12.04 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
44 12.03 IFNG IFNGR1 NOS2 TLR4
45 12.02 IFNG IL10 IL1B ITGAM NOS2 TLR2
46 11.99 IFNG IL10 IL1B IL4 IL5 ITGAM
47 11.96 ITGAM TLR2 TLR4 TLR9
48 11.96 IL10 IL1A IL1B ITGAM NOS2 TLR4
49 11.94 IFNG IL10 IL1B ITGAM TLR9 TNF
50
Show member pathways
11.93 IFNG IFNGR1 IL1B

GO Terms for Leishmaniasis

Cellular components related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 IFNG IL10 IL1A IL1B IL4 IL5
2 lysosome GO:0005764 9.55 HLA-DQA1 HLA-DRB1 IL1B SLC11A1 TLR9
3 endosome membrane GO:0010008 9.02 HLA-DQA1 HLA-DRB1 SLC11A1 TLR4 TLR9

Biological processes related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.99 IL10 NOS2 TLR4 TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 IL1B TLR2 TLR4 TLR9 TNF
3 positive regulation of DNA binding transcription factor activity GO:0051091 9.97 IL10 IL1B IL5 TNF
4 response to lipopolysaccharide GO:0032496 9.97 IL10 IL1B NOS2 SLC11A1 TLR2 TLR4
5 positive regulation of gene expression GO:0010628 9.97 IFNG IL1A IL1B SLC11A1 TLR2 TLR4
6 defense response to Gram-negative bacterium GO:0050829 9.95 NOS2 SLC11A1 TLR4 TLR9
7 positive regulation of JNK cascade GO:0046330 9.94 IL1B TLR4 TLR9 TNF
8 interferon-gamma-mediated signaling pathway GO:0060333 9.94 HLA-DQA1 HLA-DRB1 IFNG IFNGR1
9 regulation of insulin secretion GO:0050796 9.93 IFNG IL1B NOS2 TNF
10 positive regulation of inflammatory response GO:0050729 9.91 TLR2 TLR4 TLR9
11 positive regulation of tumor necrosis factor production GO:0032760 9.89 TLR2 TLR4 TLR9
12 toll-like receptor signaling pathway GO:0002224 9.88 TLR2 TLR4 TLR9
13 positive regulation of interferon-gamma production GO:0032729 9.87 IL1B SLC11A1 TLR4 TNF
14 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.86 IL1A IL1B TNF
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 IFNG IL1B TLR4 TNF
16 response to bacterium GO:0009617 9.85 NOS2 SLC11A1 TLR4
17 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.85 TLR2 TLR4 TLR9
18 positive regulation of phagocytosis GO:0050766 9.85 IL1B SLC11A1 TNF
19 positive regulation of cytokine secretion GO:0050715 9.85 IL10 IL1A TNF
20 positive regulation of B cell proliferation GO:0030890 9.85 IL4 IL5 TLR4 TLR9
21 negative regulation of interferon-gamma production GO:0032689 9.84 HLA-DRB1 IL10 TLR4
22 positive regulation of interferon-beta production GO:0032728 9.83 TLR2 TLR4 TLR9
23 positive regulation of interleukin-10 production GO:0032733 9.83 TLR2 TLR4 TLR9
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.81 IFNG IL1B TNF
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 IL1B TLR2 TLR4 TNF
26 inflammatory response GO:0006954 9.81 IL10 IL1A IL1B IL5 SLC11A1 TLR2
27 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.8 TLR2 TLR4 TLR9
28 response to molecule of bacterial origin GO:0002237 9.79 IL10 TLR2 TLR9
29 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.79 IL10 IL1B TNF
30 I-kappaB phosphorylation GO:0007252 9.78 TLR2 TLR4 TLR9
31 negative regulation of interleukin-6 production GO:0032715 9.78 IL10 TLR4 TLR9 TNF
32 regulation of cytokine secretion GO:0050707 9.77 TLR2 TLR4 TLR9
33 positive regulation of interleukin-12 production GO:0032735 9.76 IFNG TLR2 TLR4 TLR9
34 positive regulation of podosome assembly GO:0071803 9.74 IL5 TNF
35 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.74 IL1A IL1B
36 T-helper 1 type immune response GO:0042088 9.74 HLA-DRB1 TLR4
37 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.74 IL1A IL1B
38 negative regulation of interleukin-17 production GO:0032700 9.74 IFNG TLR4
39 cellular response to lipoteichoic acid GO:0071223 9.74 TLR2 TLR4
40 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.74 IL1B TLR9
41 macrophage activation GO:0042116 9.73 SLC11A1 TLR4
42 positive regulation of chemokine biosynthetic process GO:0045080 9.73 IL1B TNF
43 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.73 TLR4 TNF
44 endothelial cell apoptotic process GO:0072577 9.73 IL10 TNF
45 regulation of establishment of endothelial barrier GO:1903140 9.73 IL1B TNF
46 positive regulation of chemokine production GO:0032722 9.73 TLR2 TLR4 TLR9 TNF
47 ectopic germ cell programmed cell death GO:0035234 9.72 IL1A IL1B
48 positive regulation of interferon-beta biosynthetic process GO:0045359 9.72 TLR4 TLR9
49 negative regulation of cytokine secretion involved in immune response GO:0002740 9.72 IL10 TNF
50 type 2 immune response GO:0042092 9.72 IL10 IL4

Molecular functions related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.26 HLA-DQA1 HLA-DRB1
2 cytokine activity GO:0005125 9.17 IFNG IL10 IL1A IL1B IL4 IL5
3 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4
4 interleukin-1 receptor binding GO:0005149 9.13 IL1A IL1B TLR9

Sources for Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....